Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts

Journal of Alzheimer's Disease

Volumn 43, Issue 4, 2014, Pages 1355-1373

  Muenchhoff, Julia ^a   Poljak, Anne ^a,b   Song, Fei ^a   Raftery, Mark ^b   Brodaty, Henry ^a   Duncan, Mark ^d,e,f   McEvoy, Mark ^g   Attia, John ^g   Schofield, Peter W ^g,h   Sachdev, Perminder S ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e BIODESIX INC   (United States)

^f KING SAUD UNIVERSITY   (Saudi Arabia)

^g UNIVERSITY OF NEWCASTLE   (Australia)

^h UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Alzheimer's disease; apolipoproteins; biomarkers; complement system proteins; fibrinogen; fibronectin; mild cognitive impairment; plasma; proteomics; vitamin D binding protein

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN; APOLIPOPROTEIN A4; BIOLOGICAL MARKER; CERULOPLASMIN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT FACTOR H; FIBRONECTIN; METAL; METHAQUALONE; PLASMA PROTEIN; VITAMIN D; VITAMIN D BINDING PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; COGNITION; COMPLEMENT SYSTEM; CONTROLLED STUDY; FEMALE; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; VERY ELDERLY; BLOOD; BLOOD ANALYSIS; COHORT ANALYSIS; COMPARATIVE STUDY; MIDDLE AGED;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

EID: 84919915106     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141266     Document Type: Article

References (93)

1. Wimo A, PrinceM(2010)World Alzheimer Report 2010: The Global Economic Impact of Dementia, Alzheimer's Disease International, London.
2. Hampel H (2012) Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention. Int Psychogeriatr 24(Suppl 1), S10-S17.
3. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
4. Anderson NL, Anderson NG (2002) The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1, 845-867.
5. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050.
6. Crehan H, Hardy J, Pocock J (2012) Microglia, Alzheimer's disease, and complement. Int J Alzheimers Dis 2012, 983640.
7. Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, Nelson SK, Williams S, Hodges A, Johnston C, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Newhouse S, Lovestone S, Dobson RJ (2014) Candidate blood proteome markers of Alzheimer's disease onset and progression: A systematic review and replication study. J Alzheimers Dis 38, 515-531.
8. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
9. Llano DA, Devanarayan V, Simon AJ, Alzheimer's Disease Neuroimaging I (2013) Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 27, 233-243.
10. Ijsselstijn L, Papma JM, Dekker LJ, Calame W, Stingl C, Koudstaal PJ, Prins ND, Sillevis Smitt PA, Luider TM (2013) Serum proteomics in amnestic mild cognitive impairment. Proteomics 13, 2526-2533.
11. Thambisetty M, Simmons A,Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67, 739-748.
12. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM,Morris JC, Trojanowski JQ, Soares H, Alzheimer's Disease Neuroimaging I (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79, 897-905.
13. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM, Biomarkers Consortium Alzheimer's Disease Plasma Proteomics P (2012) Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 69, 1310-1317.
14. Cocciolo A, Di Domenico F, Coccia R, Fiorini A, Cai J, Pierce WM,Mecocci P, ButterfieldDA, PerluigiM(2012) Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. Free Radic Biol Med 53, 1868-1876.
15. Song F, Poljak A, Kochan N, Raftery M, Brodaty H, Smythe G, Sachdev P (2014) Plasma protein profiling of mild cognitive impairment and Alzheimer's disease using iTRAQ quantitative proteomics. Proteome Sci 12, 5.
16. McEvoy M, Smith W, D'Este C, Duke J, Peel R, Schofield P, Scott R, Byles J, Henry D, Ewald B, Hancock S, Smith D, Attia J (2010) Cohort profile: The Hunter Community Study. Int J Epidemiol 39, 1452-1463.
17. Sachdev PS, Brodaty H, Reppermund S, Kochan NA, Trollor JN, Draper B, Slavin MJ, Crawford J, Kang K, Broe GA, Mather KA, Lux O, Memory, Ageing Study T (2010) The SydneyMemory and Ageing Study (MAS): Methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years. Int Psychogeriatr 22, 1248-1264.
18. Schofield PW, Lee SJ, Lewin TJ, Lyall G, Moyle J, Attia J, McEvoy M (2010) The Audio Recorded Cognitive Screen (ARCS): A flexible hybrid cognitive test instrument. J Neurol Neurosurg Psychiatry 81, 602-607.
19. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
20. Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H (1998) The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr Cogn Disord 9(Suppl 2), 20-26.
21. Lim YA, Rhein V, Baysang G, Meier F, Poljak A, Raftery MJ, Guilhaus M, Ittner LM, Eckert A, Gotz J (2010) Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics 10, 1621-1633.
22. Williams TJ, Burg DW, Ertan H, Raftery MJ, Poljak A, Guilhaus M, Cavicchioli R (2010) Global proteomic analysis of the insoluble, soluble, and supernatant fractions of the psychrophilic archaeon Methanococcoides burtonii. Part II: The effect of different methylated growth substrates. J Proteome Res 9, 653-663.
23. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, Jensen LJ (2013)STRINGv9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41, D808-815.
24. Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA, Mallick P, Katz JE, Malmstrom J, Ossola R, Watts JD, Lin B, Zhang H, Moritz RL, Aebersold R (2011) A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 10, M110 006353.
25. Wang J, TYin L, Chen Z (2011) New insights into the altered fibronectin matrix and extrasynaptic transmission in the ageing brain. J Clini Gerontol Geriatr 2, 35-41.
26. Lemanska-Perek A, Leszek J, Krzyzanowska-Golab D, Radzik J, Katnik-Prastowska I (2009) Molecular status of plasma fibronectin as an additional biomarker for assessment of Alzheimer's dementia risk. Dement Geriatr Cogn Disord 28, 338-342.
27. Martin H, Lambert MP, Barber K, Hinton S, KleinWL(1995) Alzheimer's-associated phospho-tau epitope in human neuroblastoma cell cultures: Up-regulation by fibronectin and laminin. Neuroscience 66, 769-779.
28. Maas C, Schiks B, Strangi RD, Hackeng TM, Bouma BN, Gebbink MF, Bouma B (2008) Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs. Amyloid 15, 166-180.
29. Hawkes CA, Hartig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, Carare RO (2011) Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol 121, 431-443.
30. De Gasperi R, Sosa MAG, Elder GA (2012) Presenilin-1 regulates the constitutive turnover of the fibronectin matrix in endothelial cells. BMC Biochem 13, 28.
31. Guntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL,Ward MA, Lovestone S (2010) Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis 21, 585-596.
32. Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S, Johnston C, Killick R, Simmons A, Westman E, Hodges A, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, the AddNeuroMed C, Dobson RJ (2014) Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement. doi: 10.1016/j.jalz.2013.09.016
33. Liao PC, Yu L, Kuo CC, Lin C, Kuo YM (2007) Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics Clin Appl 1, 506-512.
34. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9, 293-348.
35. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 61, 120-129.
36. Zabel M, Schrag M, Mueller C, Zhou WD, Crofton A, Petersen F, Dickson A, Kirsch WM (2012) Assessing candidate serum biomarkers for Alzheimer's disease: A longitudinal study. J Alzheimers Dis 30, 311-321.
37. Chun RF (2012) New perspectives on the vitamin D binding protein. Cell Biochem Funct 30, 445-456.
38. Lu'o'ng KV, Nguyen LT (2013) The role of vitamin D in Alzheimer's disease: Possible genetic and cell signaling mechanisms. Am J Alzheimers Dis Other Demen 28, 126-136.
39. Smolders J, Moen SM, Damoiseaux J, Huitinga I, Holmoy T (2011) Vitamin D in the healthy and inflamed central nervous system: Access and function. J Neurol Sci 311, 37-43.
40. Moon M, Song H, Hong HJ, NamDW, ChaMY,OhMS,Yu J, Ryu H, Mook-Jung I (2013) Vitamin D-binding protein interacts with A beta and suppresses A beta-mediated pathology. Cell Death Differ 20, 630-638.
41. Hellman NE, Gitlin JD (2002) Ceruloplasmin metabolism and function. Annu Rev Nutr 22, 439-458.
42. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S (2002) Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci 22, 6578-6586.
43. Vassiliev V, Harris ZL, Zatta P (2005) Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 49, 633-640.
44. Ayton S, Lei P, Bush AI (2013) Metallostasis in Alzheimer's disease. Free Radic Biol Med 62, 76-89.
45. Giometto B, Argentiero V, Sanson F, Ongaro G, Tavolato B (1988) Acute-phase proteins in Alzheimer's disease. Eur Neurol 28, 30-33.
46. Kessler H, Pajonk FG, Meisser P, Schneider-Axmann T, Hoffmann KH, Supprian T, Herrmann W, Obeid R, Multhaup G, Falkai P, Bayer TA (2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. J Neural Transm 113, 1763-1769.
47. Park JH, Lee DW, Park KS (2014) Elevated serum copper and ceruloplasmin levels in Alzheimer's disease. Asia Pac Psychiatry 6, 38-45.
48. Rembach A, Doecke JD, Roberts BR, Watt AD, Faux NG, Volitakis I, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, WilsonW, Ellis KA, Martins RN, Rowe CC, Villemagne VL, Ames D, Masters CL, Bush AI, Grp AR (2013) Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. J Alzheimers Dis 34, 171-182.
49. Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Holbrook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Wille DR, Wu W, Yates JW, Gloger IS (2008) Proteomic identification and early validation of complement 1 inhibitor and pigment epitheliumderived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin Appl 2, 467-477.
50. Licastro F, Morini MC, Polazzi E, Davis LJ (1995) Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: An acute phase reactant without the peripheral acute phase response. J Neuroimmunol 57, 71-75.
51. Squitti R, Ventriglia M, Barbati G, Cassetta E, Ferreri F, Dal Forno G, Ramires S, Zappasodi F, Rossini PM (2007) 'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function. J Neural Transm 114, 1589-1594.
52. Sedighi BS, Shafa MA, Shariat M (2006) A study of serum copper and ceruloplasmin in Alzheimer's disease in Kerman, Iran. Neurol Asia 11, 107-109.
53. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, Dick R (2010) Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am J Alzheimers Dis Other Demen 25, 490-497.
54. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir, Baldvinsson M, Johannesson T (1998) Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. a case-control study. Dement Geriatr Cogn Disord 9, 239-242.
55. Torsdottir G, Kristinsson J, Snaedal J, Johannesson T (2011) Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra 1, 366-371.
56. Holmes C, Butchart J (2011) Systemic inflammation and Alzheimer's disease. Biochem Soc Trans 39, 898-901.
57. AiyazM,LuptonMK,Proitsi P, Powell JF,Lovestone S (2012) Complement activation as a biomarker for Alzheimer's disease. Immunobiology 217, 204-215.
58. Veerhuis R, Nielsen HM, Tenner AJ (2011) Complement in the brain. Mol Immunol 48, 1592-1603.
59. Strohmeyer R, Shen Y, Rogers J (2000) Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res 81, 7-18.
60. Lukiw WJ, Alexandrov PN(2012) Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's disease (AD) brain. Mol Neurobiol 46, 11-19.
61. Trouw LA, Nielsen HM, Minthon L, Londos E, Landberg G, Veerhuis R, Janciauskiene S, Blom AM (2008) C4b-binding protein in Alzheimer's disease: Binding to Abeta1-42 and to dead cells. Mol Immunol 45, 3649-3660.
62. Gezen-Ak D, Dursun E, Hanagasi H, Bilgic B, Lohman E, Araz OS, Atasoy I, Alaylioglu M, Onal B, Gurvit H, Yilmazer S (2013) BDNF, TNFalpha, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer's disease or mild cognitive impairment. J Alzheimers Dis 37, 185-195.
63. Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A, Simmons A, Murphy D, Lovestone S (2008) Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 255, 1712-1720.
64. Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C, Kupchak P, Kireeva I, Ingratta L, Jackowski G (2004) Mining biomarkers in human sera using proteomic tools. Proteomics 4, 244-256.
65. Sarvari M, Vago I,Weber CS, Nagy J, Gal P, MakM, Kosa JP, Zavodszky P, Pazmany T (2003) Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity. J Neuroimmunol 137, 12-18.
66. Veerhuis R, Janssen I, De Groot CJ,Van Muiswinkel FL, Hack CE, Eikelenboom P (1999) Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp Neurol 160, 289-299.
67. Veerhuis R, Janssen I, Hoozemans JJ, De Groot CJ, Hack CE, Eikelenboom P (1998) Complement C1-inhibitor expression in Alzheimer's disease. Acta Neuropathol 96, 287-296.
68. Finehout EJ, Franck Z, Lee KH (2005) Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 21, 93-101.
69. Jongen PJ, Doesburg WH, Ibrahim-Stappers JL, Lemmens WA, Hommes OR, Lamers KJ (2000) Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 101, 116-121.
70. Hardy J, Guerreiro R, Lovestone S (2011) Clusterin as an Alzheimer biomarker. Arch Neurol 68, 1459-1460.
71. Schrijvers EM,Koudstaal PJ, Hofman A, BretelerMM(2011) Plasma clusterin and the risk of Alzheimer disease. JAMA305, 1322-1326.
72. Song F, Poljak A, Crawford J, Kochan NA,WenW, Cameron B, Lux O, Brodaty H, Mather K, Smythe GA, Sachdev PS (2012) Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One 7, e34078.
73. Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, Guntert A, Kraut M, Ferrucci L, Davatzikos C, Lovestone S, Resnick SM (2012) Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59, 212-217.
74. Bhamra MS, Ashton NJ (2012) Finding a pathological diagnosis for Alzheimer's disease: Are inflammatory molecules the answer? Electrophoresis 33, 3598-3607.
75. Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH (2012) Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimers Dis 32, 599-608.
76. Giambattistelli F, Bucossi S, Salustri C, Panetta V, Mariani S, Siotto M, Ventriglia M, Vernieri F, Dell'acqua ML, Cassetta E, Rossini PM, Squitti R (2012) Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. Neurobiol Aging 33, 1633-1641.
77. Xu G, Zhang H, Zhang S, FanX, LiuX(2008) Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int J Clin Pract 62, 1070-1075.
78. van Oijen M,Witteman JC, Hofman A,Koudstaal PJ, Breteler MM (2005) Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36, 2637-2641.
79. Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, Wahlund LO, Kinsey A, Causevic M, Killick R, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S, AddNeuroMed C (2011) Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One 6, e28527.
80. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 6, e18850.
81. Lee JW, Namkoong H, Kim HK, Kim S, Hwang DW, Na HR, Ha SA, Kim JR, Kim JW (2007) Fibrinogen gamma-A chain precursor in CSF: A candidate biomarker for Alzheimer's disease. BMC Neurol 7, 14.
82. Vafadar-Isfahani B, Ball G, Coveney C, Lemetre C, Boocock D, Minthon L, Hansson O, Miles AK, Janciauskiene SM, Warden D, Smith AD, Wilcock G, Kalsheker N, Rees R, Matharoo-Ball B, Morgan K (2012) Identification of SPARClike 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. J Alzheimers Dis 28, 625-636.
83. Kim SM, Song J, Kim S, Han C, Park MH,KohY, Jo SA, Kim YY (2011) Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol 11, 51.
84. YaffeK, Petersen RC, Lindquist K, Kramer J, Miller B (2006) Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 22, 312-319.
85. Trollor JN, Smith E, Agars E, Kuan SA, Baune BT, Campbell L, Samaras K, Crawford J, Lux O, Kochan NA, Brodaty H, Sachdev P (2012) The association between systemic inflammation and cognitive performance in the elderly: The Sydney Memory and Ageing Study. Age (Dordr) 34, 1295-1308.
86. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, HoltzmanDM,Dominantly Inherited AlzheimerN (2014) Longitudinal change in CSF biomarkers in autosomaldominant Alzheimer's disease. Sci Transl Med 6, 226ra230.
87. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69, 1318-1325.
88. Burnham SC, Faux NG,WilsonW, Laws SM, Ames D, Bedo J, Bush AI, Doecke JD, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe CC, Salvado O, Macaulay SL, Masters CL, Villemagne VL, Alzheimer's Disease Neuroimaging I, Australian Imaging B, Lifestyle Study Research G (2014) A blood-based predictor for neocortical Abeta burden in Alzheimer's disease: Results from the AIBL study. Mol Psychiatry 19, 519-526.
89. Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, Lui JK, Masters C, Rowe CC, Szoeke C, Taddei K, Martins RN, Group AR (2011) Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging. Neurology 76, 1091-1098.
90. Gautam P, Nair SC, Gupta MK, Sharma R, Polisetty RV, Uppin MS, Sundaram C, Puligopu AK, Ankathi P, Purohit AK, Chandak GR, Harsha HC, Sirdeshmukh R (2012) Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS One 7, e46153.
91. Blanton D, Han Z, Bierschenk L, Linga-Reddy MV, Wang H, Clare-Salzler M, Haller M, Schatz D, Myhr C, She JX, Wasserfall C, Atkinson M (2011) Reduced serum vitamin Dbinding protein levels are associated with type 1 diabetes. Diabetes 60, 2566-2570.
92. Tracy RP (2008) 'Deep phenotyping': Characterizing populations in the era of genomics and systems biology. Curr Opin Lipidol 19, 151-157.
93. Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lonneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjogren M, Hu W, Lovestone S, Karsdal MA,WeinerMW, Blood-Based Biomarker InterestG (2014) The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 10, 115-131.